APICOPLAST: A BRILLIANT FOCUS FOR ANTIMALARIAL DRUG DEVELOPMENT

 

 

FUTURE PROSPECTS 
Mixture remedy is the contemporary desire to retard and roll-back the resistance disaster and might be the most effective alternative to be had to increase the working lifestyles of medication which can be at the front-line within the warfare against malaria. Aside from delaying the emergence of resistance, it is a bare fact that a mixture of two tablets that act on distinct goals (enzymes) in the equal metabolic pathway may additionally give correct efficacy and toxicological profiles. The search for the goals to discover new antimalarial drug has been made by way of the identity of recent capability objectives in apicoplastic metabolic pathways, which might be recognized to be evolutionarily distant from the ones of the human beings. Following this a number acknowledged and new lead compounds were screened for his or her inhibitory interest in opposition to metabolic enzymes like DXR, DXS and FPPS in isoprenoid pathway; ENR, the KAS family, KAR and HAD in FAS II; and ALAD and PPO in heme synthesis pathways. The current advances within the in vitro antimalarial screening assays by way of the usage of the entire parasites, we can10 desire that there stays a lot to be completed inside the pursuit of new mixtures of medicine which target distinct enzymes belonging to at least one unique metabolic pathway. Apicoplast is essential for growth and survival of the malaria parasite and has been notably centered. It houses vital biosynthetic pathways as well as prokaryotic like house responsibilities techniques presenting appealing avenues for drug improvement. The discovery of the susceptibility of the apicoplast to antimicrobial antibiotics has pushed giant research into the discovery of novel apicoplast targeting compounds. The apicoplast metabolic methods especially the prokaryote like fatty acid biosynthetic pathway has been drastically targeted over the latest years using medicinal chemistry and SAR based totally procedures.

REFERENCES
1. Alonso, P., & Noor, A. M. The global fight against malaria is at crossroads. The Lancet, 2017, 390 (10112), 2532-2534.
2. Bhatt, S., Weiss, D., Cameron, E., Bisanzio, D., Mappin, B., Dalrymple, U., Eckhoff, P, The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature 2015, 526(7572), 207.
3. Brochet, M., Collins, M. O., Smith, T. K., Thompson, E., Sebastian, S., Volkmann, K., Berriman, M. Phosphoinositide metabolism links cGMP-dependent protein kinase G to essential Ca2+ signals at key decision points in the life cycle of malaria parasites. PLoS biology, 2014, 12(3), e1001806.
4. Burger, R. J., van Eijk, A. M., Bussink, M., Hill, J., & ter Kuile, F. O. Artemisinin-based combination therapy versus quinine or other combinations for treatment of uncomplicated Plasmodium falciparum malaria in the second and third trimester of pregnancy: a systematic review and meta-analysis. Paper presented at the Open forum infectious diseases, 2016
5. Chakraborty, A. . Understanding the biology of the Plasmodium falciparum apicoplast; an excellent target for antimalarial drug development. Life sciences, 2016, 158, 104-110.
6. Chibale, K. , How Africa is helping expand the global antimalarial drug pipeline: health research, 2016,  Quest, 12(3), 22-23.
7. Diagana, T. T. Supporting malaria elimination with 21st century antimalarial agent drug discovery. Drug discovery today, 2015, 20(10), 1265-1270.
8. Gamo, F.-J.  Antimalarial drug resistance: new treatments options for Plasmodium. Drug Discovery Today: Technologies, 2014, 11, 81-88.
9. Goodman, C. D., Su, V., & McFadden, G. I. The effects of anti-bacterials on the malaria parasite Plasmodium falciparum. Molecular and biochemical parasitology, 2007, 152(2), 181-191.
10. Götz, A., Ty, M., Chora, A. F., Zuzarte-Luís, V., Mota, M. M., & Rodriguez, A. Innate Immunity to Malaria Malaria 2017, (pp. 3-25): Springer.
11. Hemingway, J., Shretta, R., Wells, T. N., Bell, D., Djimdé, A. A., Achee, N., & Qi, G. Tools and strategies for malaria control and elimination: what do we need to achieve a grand convergence in malaria? PLoS biology, 2016, 14(3), e1002380.
12. Insecticide, m. R. C. P. o., & Resistance, D. malERA: An updated research agenda for insecticide and drug resistance in malaria elimination and eradication. PLoS medicine, 2017, 14(11), e1002450.
13. Jackson, B. D., & Black, R. E. (2017). A literature review of the effect of malaria on stunting. The Journal of nutrition, 2017, 147(11), 2163S-2168S.
14. Jomaa,  H.,  Wiesner,  J.,  Sanderbrand,  S.,  Altincicek,  B.,  Weidemeyer,  C.,  Hintz,  M.,  .  .  .
15. Lichtenthaler, H. K. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science, 1999, 285(5433), 1573-1576.
16. Ke, H., Lewis, I. A., Morrisey, J. M., McLean, K. J., Ganesan, S. M., Painter, H. J., . . . Vaidya, A. B. Genetic investigation of tricarboxylic acid metabolism during the Plasmodium falciparum life cycle. Cell reports, 2015, 11(1), 164-174.
17. Lim, L., Sayers, C. P., Goodman, C. D., & McFadden, G. I. (2016). Targeting of a transporter to the outer apicoplast membrane in the human malaria parasite Plasmodium falciparum. PloS one, 2016, 11(7), e0159603.
18. Siciliano, G., & Alano, P.. Enlightening the malaria parasite life cycle: bioluminescent Plasmodium in fundamental and applied research. Frontiers in microbiology, 6, 391.
19. Tesfaye, S., Prakash, B., & Singh, P. P. . Apicoplast Biosynthetic Pathways as Possible Targets for Combination Therapy of Malaria. Journal of Pharmacy and Pharmacology, 2015, 3(1), 101-115.
20. Thwing, J., Eckert, E., Dione, D. A., Tine, R., Faye, A., Yé, Y., Diouf, M. B. Declines in Malaria Burden and All-Cause Child Mortality following Increases in Control Interventions in Senegal, 2005–2010. The American journal of tropical medicine and hygiene, 2017, 97(3_Suppl), 89-98.
21. Uddin, T., McFadden, G. I., & Goodman, C. D. Validation of Putative Apicoplast-Targeting Drugs Using a Chemical Supplementation Assay in Cultured Human Malaria Parasites. Antimicrobial agents and chemotherapy, 2018, 62(1), e01161-01117.
22. Visser, B. J., Wieten, R. W., Kroon, D., Nagel, I. M., Bélard, S., van Vugt, M., & Grobusch, M. P. Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review. Malaria journal, 2014, 13(1), 463.
23. Wiley, J. D., Merino, E. F., Krai, P. M., McLean, K. J., Tripathi, A. K., Vega-Rodríguez, J., Cassera, M. B. Isoprenoid precursor biosynthesis is the essential metabolic role of the apicoplast during gametocytogenesis in Plasmodium falciparum. Eukaryotic cell, 2015, 14(2), 128-139.
24. Wu, W., Herrera, Z., Ebert, D., Baska, K., Cho, S. H., DeRisi, J. L., & Yeh, E. A chemical rescue screen identifies a Plasmodium falciparum apicoplast inhibitor targeting MEP isoprenoid precursor biosynthesis. Antimicrobial agents and chemotherapy, 2015, 59(1), 356-364.

NOW YOU CAN ALSO PUBLISH YOUR ARTICLE ONLINE.

SUBMIT YOUR ARTICLE/PROJECT AT editor-in-chief@pharmatutor.org

Subscribe to Pharmatutor Alerts by Email

FIND OUT MORE ARTICLES AT OUR DATABASE


Pages

FIND MORE ARTICLES